Share this page!

Enter URL or ID to Unroll

You can paste full URL like: https://x.com/threadreaderapp/status/1644127596119195649
or just the ID like: 1644127596119195649

How to get URL link on X (Twitter) App

  1. On the Twitter thread, click on or icon on the bottom
  2. Click again on or Share Via icon
  3. Click on Copy Link to Tweet
  4. Paste it above and click "Unroll Thread"!
  5. More info at Twitter Help
Eli Van Allen Profile picture
Eli Van Allen
@VanAllenLab
LA | @Stanford '03 | @UCLA MD '07 | @UCSF IM '10 | Now: @DanaFarber @broadinstitute @harvardmed clinical computational oncology! Discl.: https://t.co/XkFZSwd04f
Aug 29, 2018 • 13 tweets • 9 min read
A thread on our latest look at cancer genomics + immune checkpoint blockade → congrats @diana_miao, Claire, @NIVokes et al!

Thx @SU2C @BroadIgnite @HHMINEWS @theNCI for supporting this & the ppl doing it @NatureGenet @DanaFarber @broadinstitute

rdcu.be/5iVz [1/n] We analyzed every tumor-normal exome from patients getting immune checkpoint blockade (ICB) we could get & integrated w/ clinical outcomes for biological and clinical exploration → lots of technical pain here + open questions re: defining clinical benefit
Aug 9, 2018 • 4 tweets • 2 min read
Lots of discussion whether broad cancer NGS testing is good/bad given @JAMAOnc article below. Tbh I'm far more interested in some general issues it exposes re: prospectively testing the precision oncology hypothesis:

jamanetwork.com/journals/jama/… [1/4] 1) NGS testing w/o companion (early phase?) clinical trial network & mid-trial adjustments for when new approvals arise creates a ‘last mile’ problem that reduces potential impact. Can a precision oncology trial have experimental Rx access and be changed in real time? [2/4]
Apr 25, 2018 • 6 tweets • 3 min read
Reflecting on the recent/heated “hype vs. hope” precision oncology debates: It’s not “vs.” → real hope it engenders & current limitations are simultaneously true. This tension mirrors so much of oncology, as @Bob_Wachter elegantly points out here:
nytimes.com/2018/04/19/opi… [1/n] Thankfully, @DHymanMD captured this critical point clearly, here:
Apr 3, 2018 • 11 tweets • 12 min read
A twitter explainer for our latest #teamscience study rdcu.be/KwgV congrats Josh @stephanie_mul @dliu_ccb @nikolausschultz Arul @CharlesSawyers et al @PCFnews @SU2C @DanaFarber @broadinstitute @MSKCC_OncoNotes @NatureGenet [1/n] I've been lucky to grow up academically around many #prostatecancer scientific 'big machers' & helped with early cancer genomic maps over the last 5+ years, e.g.:
1) rdcu.be/Kw8d (@Chris_Barbieri1)
2) cell.com/cell/fulltext/…
3) cell.com/abstract/S0092… (@NCIgenomics)
Mar 2, 2018 • 10 tweets • 6 min read
A twitter explainer on our latest study, Inherited DNA Repair Defects in Colorectal Cancer – congrats @s_aldubayan @MattYurgelun @SapnaSyngal et al! @DanaFarber @broadinstitute @DamonRunyon @AJHGNews authors.elsevier.com/a/1Web9geWqOxr There’s an established heritability for colorectal cancer hovering around 30%, though only roughly 5-10% is explained by known syndromes involving genes like APC, MSH2, and PTEN, among others – the rest is so-called “missing heritability”